Organogenesis Holdings Inc. ORGO

ORGO Company Overview

Organogenesis Holdings Inc. is a regenerative medicine company focused on advanced wound care, surgical and sports medicine, and regenerative and cellular therapies. The company develops, manufactures, and commercializes products designed to repair and regenerate tissue, with a primary emphasis on chronic and acute wound management. Organogenesis operates within the broader biotechnology, medical device, and regenerative medicine industries, serving hospitals, wound care centers, outpatient clinics, physician offices, ambulatory surgery centers, and government healthcare systems.

The company’s principal revenue drivers are its portfolio of bioactive and acellular tissue products marketed through its Advanced Wound Care and Surgical & Sports Medicine business lines. Key products include Apligraf, Dermagraft, Affinity, NuShield, PuraPly AM, and ReNu. Organogenesis has historically differentiated itself through expertise in living cell-based therapies, tissue processing capabilities, and an established commercial infrastructure focused on wound care specialists and surgeons. The company traces its origins to the 1980s and became recognized for pioneering bioengineered skin substitutes. Following multiple ownership and restructuring periods, Organogenesis returned to the public markets through a merger with a special purpose acquisition company in 2020.